about
Basic Concepts in Population Modeling, Simulation, and Model-Based Drug DevelopmentIntegrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide.PKreport: report generation for checking population pharmacokinetic model assumptions.Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo.Population pharmacokinetics of theophylline during paediatric extracorporeal membrane oxygenation.A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979)Assessment of the validity of a population pharmacokinetic model for epirubicin.Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic Studies.External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients.Controlled cellular uptake and drug efficacy of nanotherapeuticsSafety and pharmacokinetics of multiple dose myo-inositol in preterm infants.Fundamentals of population pharmacokinetic modelling: validation methods.Enhancing population pharmacokinetic modeling efficiency and quality using an integrated workflow.Gap analysis of pharmacokinetics and pharmacodynamics in burn patients: a review.Population Pharmacokinetics of Boosted-Elvitegravir in HIV-Infected Patients.Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery.Gastric secretion does not affect the reliability of the 13C-acetate breath test: A validation of the 13C-acetate breath test by magnetic resonance imaging.Prediction tacrolimus blood levels based on the Bayesian method in adult kidney transplant patients.Measuring the interaction of meal and gastric secretion: a combined quantitative magnetic resonance imaging and pharmacokinetic modeling approach.In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients.Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients.Population Pharmacokinetics of Diazoxide in Children with Hyperinsulinemic Hypoglycemia.
P2860
Q29013931-D12C2363-0DEB-4128-99A6-13EAA137BF21Q33809839-978F2D1A-BA70-4CCA-97C6-AEED9B32E1BEQ33901595-01EA9C2B-082D-45F5-B3C5-7B6A2568AEECQ34592125-E9DE05F6-50E9-4F95-9975-9EAEA1878DFDQ35825168-2FAE567C-753E-43F0-A691-DDACFA55AAA3Q35825630-7250F5A3-7BF9-43EC-9C89-F4B0024575CFQ35827620-B9D1ED75-ABFA-41E2-B03A-3982135035AFQ35928858-DE7BDEBF-989D-474E-A527-AF65610692EEQ36806621-21D90AE9-F56B-402D-A315-68096E386D99Q36932025-1CE60FBA-F959-4C59-8036-DB7624F5F30DQ37544118-99C06B92-F8CB-4816-81C0-2FD634A7741DQ38026590-DA059CDD-3425-4A4D-B2D6-6AB4D1266FABQ38233301-F01FAEB7-C588-43C3-BE6A-F7A319E6D0FBQ38459977-E1BD3A5B-3431-43D8-8B70-F8BE7D256321Q40452205-41D0887E-364A-4ABB-BE13-292A8DD6B3BDQ42632207-C107157B-3889-4DD5-9057-9681FCE68D14Q43753931-3BC510B6-B893-4995-B1BD-D6FDBE2B3AE5Q43877187-5A523D83-0F9F-4062-BFA7-F9C0AE925CB9Q44564164-52DE88B7-3CB9-4498-A94B-9A180CE8FB12Q45869569-1EB463C2-525A-465F-BD90-7E17C0C80286Q45978260-C19D084B-6526-461A-8F53-F469B0073EBBQ55446246-F47E7B36-E514-40F5-B860-8DFD38F382B5
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
name
Population pharmacokinetics. A regulatory perspective.
@ast
Population pharmacokinetics. A regulatory perspective.
@en
type
label
Population pharmacokinetics. A regulatory perspective.
@ast
Population pharmacokinetics. A regulatory perspective.
@en
prefLabel
Population pharmacokinetics. A regulatory perspective.
@ast
Population pharmacokinetics. A regulatory perspective.
@en
P2093
P1476
Population pharmacokinetics. A regulatory perspective
@en
P2093
E O Fadiran
R Williams
P356
10.2165/00003088-199937010-00003
P577
1999-07-01T00:00:00Z
P6179
1000638215